2022-500713-79-00进行中（未招募）2/3 期
Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC.
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2022年10月13日最近更新:
试验速览
- 阶段
- 2/3 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- The primary endpoint will be CBR defined as CR or PR at any time point and SD lasting ≥6 months after re-introduction of PD-1 inhibition by cemiplimab (Day 1 of Week 27) as defined by RECIST 1.1. The primary endpoint includes patients having a CR or PR but who show PD prior to the 6 month’ time point from start of treatment. Lesions that were irradiated as part of study treatment are not eligible as measurable disease by RECIST. Lesions that were irradiated prior to the study, but have progresse
研究概览
简要总结
Clinical benefit rate (CBR) defined as complete or partial response (CR or PR) at any time point and stable disease (SD) lasting 6 months after re-introduction of PD-1 inhibition (Day 1 of Week 27). This includes patients having response but show progressive disease (PD) prior to the 6 months’ time point from start of treatment.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Have proven diagnosis of recurrent advanced NSCLC, irrespective of histological subtype.
- •Female subject of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the 1st dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •Male subjects should agree to use an adequate method of contraception starting with the 1st dose of study therapy through 6 months after the last dose of study therapy.
- •Be willing and able to provide written informed consent/assent for the trial.
- •Be 18 years of age on day of signing informed consent.
- •Must still have measurable disease based on RECIST 1.1 after application of study SBRT. Lesions that were irradiated prior to the study, but have progressed since irradiation but prior to study inclusion will be allowed as measurable disease.
- •Must provide newly obtained tissue from a core or excisional biopsy of a tumor lesion and are willing to have a second biopsy performed from any non-irradiated lesion after the radiation and immune-modulating treatment. This lesion may be used for RECIST measurements.
- •Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •Stage IV NSCLC treated with at least PD-(L)1 blockade. There is no maximum number of previous lines of systemic treatment. Patients with both primary or acquired resistance to PD-(L)1 inhibition may be considered eligible. However, in the 1st stage ≥4 of 12 patients, in the 2nd stage a total of ≥8 of 25 patients and in the 3rd stage a total of ≥27 of 54 patients need to fulfill the definition of acquired resistance. Also, a maximum of 27 patients with a PD-L1 negative tumor will be included.
- •Have at least 2 separate (metastatic) lesions of which one is eligible for irradiation and another for biopsy and RECIST tumor evaluation.
- •Demonstrate adequate organ function as defined in Table
- •All screening labs should be performed within 14 days of treatment initiation.
排除标准
- •Has a non-smoking-related targetable driver mutation, e.g. EGFR, ALK, RET or ROS
- •Patients with advanced NSCLC with a smoking-related targetable driver mutation, e.g. KRAS or BRAF, may be found eligible if they have a history of ≥10 PY, but only when all options for targeted therapy have been exhausted and when progression on previous PD-(L)1 blockade has occurred.
- •Has an active infection requiring systemic therapy.
- •Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the 1st dose of treatment.
- •Has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. o Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. o Note: Patients who experienced significant autoimmune side effects related to previous PD-(L)1 checkpoint inhibition, i.e. requiring use of steroids or other anti-inflammatory drugs and/or the need to (temporarily) withhold PD-(L)1 checkpoint inhibition, may be considered eligible after discussion with the coordinating investigator if adverse events have recovered, i.e. ≤ Grade 1 or at baseline. o Note: If subjects received major surgery (defined as surgical intervention requiring general or spinal anesthesia and hospital admission), they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. Major surgery within 14 days prior to start of study treatment is not allowed.
- •Has had previous radical radiation to any tumor site within 3 months prior to study Day
- •Previous palliative radiation to any tumor site is not considered an exclusion criterion; however, this site will not be eligible for SBRT, biopsy location or RECIST tumor evaluation within this study.
- •Has received prior therapy with any antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways other than PD-(L)1 blockade, e.g. anti-CD137 or a CTLA-4 antibody.
- •Patients who have uncontrolled central nervous system (CNS) metastases. Patients who have untreated asymptomatic CNS metastases no greater than 2cm before start of treatment may be eligible. Patients who have any CNS lesion that is symptomatic, greater than 2cm, show significant surrounding edema on MRI scan or have leptomeningeal disease will not be eligible. Patients who have previously been treated for CNS metastases are eligible when they comply with the hereby mentioned criteria. NB. A brain lesion is not amendable for study SBRT.
- •Has a known additional malignancy that is progressing or requires active treatment.
- •Has an active autoimmune disease or a documented history of clinically severe autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Subjects who require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with an active or history of autoimmune disease or syndrome who underwent previous PD-(L)1 checkpoint inhibition without significant side effects, i.e. not requiring use of steroids or other anti-inflammatory drugs and/or the need to (temporarily) withhold PD-(L)1 checkpoint inhibition, may be considered eligible for this trial after discussion with the coordinating investigator. Requirement for immunosuppressive doses of systemic corticosteroids ≤10 mg/day prednisone or equivalent may be considered eligible after discussion as well.
- •Has evidence of symptomatic interstitial lung disease or an active, non-infectious pneumonitis.
结局指标
主要结局
The primary endpoint will be CBR defined as CR or PR at any time point and SD lasting ≥6 months after re-introduction of PD-1 inhibition by cemiplimab (Day 1 of Week 27) as defined by RECIST 1.1. The primary endpoint includes patients having a CR or PR but who show PD prior to the 6 month’ time point from start of treatment. Lesions that were irradiated as part of study treatment are not eligible as measurable disease by RECIST. Lesions that were irradiated prior to the study, but have progresse
The primary endpoint will be CBR defined as CR or PR at any time point and SD lasting ≥6 months after re-introduction of PD-1 inhibition by cemiplimab (Day 1 of Week 27) as defined by RECIST 1.1. The primary endpoint includes patients having a CR or PR but who show PD prior to the 6 month’ time point from start of treatment. Lesions that were irradiated as part of study treatment are not eligible as measurable disease by RECIST. Lesions that were irradiated prior to the study, but have progresse
次要结局
- Secondary endpoints of this trial will be ORR defined as CR or PR at 12 weeks after re-introduction of PD-1 inhibition by cemiplimab (Day 1 of Week 15) and DCR defined as CR, PR or SD at 12 weeks after re-introduction of PD-1 inhibition by cemiplimab (Day 1 of Week 15). Also, best overall response at any time point, PFS defined as time between start of treatment and PD or death and OS defined as time between start of treatment and death will be secondary endpoint. Safety of the study procedures
研究者
W.S.M.E. Theelen, MD, PhD
Scientific
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapyin advanced NSCLC.Patients with advanced NSCLC who have progressed after at least previous anti-PD-(L)1 treatment and are ECOG 0-1 are allowed to participate irrespective of the level of tumor PD-L1 expression. Patients with advanced NSCLC with a targetable driver mutation may be found eligible, but only when all options for targeted therapy have been exhausted and when progression on previous PD-(L)1 blockade has occurred.CTIS2022-500713-79-00Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis54
招募中
不适用
The Immune Assessment of PD-1 Antibody Therapy in TumorEfficacy, TeamAdverse EventNCT06693440Quanli Gao3,000
尚未招募
不适用
Enhancing patients defense against TB for early recovery.CTRI/2020/03/023815Department of Biotechnology60
招募中
1 期
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaGlioblastoma MultiformeNCT04977375Chirag G. Patil10
招募中
2 期
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCEsophageal Squamous Cell Carcinoma Stage IIEsophageal Squamous Cell Carcinoma Stage IIINCT04973306Shanghai Zhongshan Hospital176